Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
6(67%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_3
2
22%
Ph phase_1
1
11%
Ph early_phase_1
1
11%
Ph phase_2
4
44%
Ph not_applicable
1
11%

Phase Distribution

2

Early Stage

4

Mid Stage

2

Late Stage

Phase Distribution9 total trials
Early Phase 1First-in-human
1(11.1%)
Phase 1Safety & dosage
1(11.1%)
Phase 2Efficacy & side effects
4(44.4%)
Phase 3Large-scale testing
2(22.2%)
N/ANon-phased studies
1(11.1%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

6

trials recruiting

Total Trials

9

all time

Status Distribution
Active(8)
Completed(1)

Detailed Status

Recruiting4
Active, not recruiting2
Not yet recruiting2
Completed1

Development Timeline

Analytics

Development Status

Total Trials
9
Active
6
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Early Phase 11 (11.1%)
Phase 11 (11.1%)
Phase 24 (44.4%)
Phase 32 (22.2%)
N/A1 (11.1%)

Trials by Status

active_not_recruiting222%
completed111%
not_yet_recruiting222%
recruiting444%

Recent Activity

6 active trials
Showing 5 of 9
not_yet_recruitingphase_2

Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem Cell Transplant Alone for High-risk Patients With Relapsed or Refractory Hodgkin Lymphoma

NCT07572123
recruitingphase_3

Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging

NCT04423211
active_not_recruitingphase_2

Single Fraction or Multi-fraction Palliative Radiation Therapy for the Improvement of Quality of Life in Patients With Metastatic Gynecologic Cancers

NCT04516135
recruitingnot_applicable

Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy for Palliative Head and Neck Cancer Treatment (PULS-Pal)

NCT06572423
recruitingphase_2

Hippocampal Avoidance in Craniospinal Irradiation for the Treatment of Leptomeningeal Metastases From Breast Cancer or Non-small Cell Lung Cancer

NCT06518057
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT07572123Phase 2

Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem Cell Transplant Alone for High-risk Patients With Relapsed or Refractory Hodgkin Lymphoma

Not Yet Recruiting
NCT04423211Phase 3

Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging

Recruiting
NCT04516135Phase 2

Single Fraction or Multi-fraction Palliative Radiation Therapy for the Improvement of Quality of Life in Patients With Metastatic Gynecologic Cancers

Active Not Recruiting
NCT06572423Not Applicable

Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy for Palliative Head and Neck Cancer Treatment (PULS-Pal)

Recruiting
NCT06518057Phase 2

Hippocampal Avoidance in Craniospinal Irradiation for the Treatment of Leptomeningeal Metastases From Breast Cancer or Non-small Cell Lung Cancer

Recruiting
NCT06910761Phase 2

Photon Craniospinal Irradiation for the Treatment of Leptomeningeal Disease Secondary to Breast Cancer or Non-small Cell Lung Cancer

Recruiting
NCT07215910Phase 3

Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer

Not Yet Recruiting
NCT04281199Phase 1

TBI Using IMRT (VMAT or Tomotherapy) for the Prevention of Pul Toxicities in Patients Undergoing Donor SCT

Active Not Recruiting
NCT03162731Early Phase 1

Nivolumab, Ipilimumab, and Radiation Therapy in Treating Patients With Stage III-IVB Head and Neck Cancer

Completed

All 9 trials loaded

Drug Details

Intervention Type
RADIATION
Total Trials
9